Indo Us Biotech Limited (INDOUS)
📢 Recent Corporate Announcements
Indo Us Biotech Limited has issued notice for its 22nd Annual General Meeting (AGM) scheduled for September 30, 2026, with the register of members closing from September 23 to September 30, 2026. Key special resolutions include enhancing the Board's borrowing limit up to ₹250 Crore over paid-up capital and free reserves, creating asset charges up to ₹100 Crore, and approving related party transactions up to ₹10 Crore per transaction type. The company has also proposed appointing M/s Bhagat & Associates as Statutory Auditors for a 5-year term ending at the 2031 AGM.
- 22nd AGM scheduled for September 30, 2026 via Video Conferencing / OAVM.
- Share transfer books and register of members closed from September 23, 2026 to September 30, 2026.
- Special resolution tabled to approve borrowing limits up to ₹250 Crore over and above paid-up capital and free reserves.
- Approval sought for creating asset charges/mortgages up to ₹100 Crore.
- Related party transactions approval sought under Section 188 up to ₹10 Crore for each transaction type.
Indo Us Biotech Limited has issued the notice for its 22nd Annual General Meeting scheduled for September 30, 2026. Key special resolutions include seeking shareholder approval for borrowing limits up to ₹250 crore over paid-up capital and reserves, creation of asset charges up to ₹100 crore, and approving related party transactions up to ₹10 crore per transaction type. The company has also proposed the appointment of M/s. Bhagat & Associates as statutory auditors for a five-year term until 2031.
- 22nd Annual General Meeting scheduled on Wednesday, September 30, 2026, via Video Conferencing.
- Proposed special resolution to approve borrowing limits of up to ₹250 crore over paid-up capital and free reserves.
- Approval sought for creation of charges/mortgages on assets up to ₹100 crore.
- Approval sought for related party transactions up to ₹10 crore for each transaction type.
- Appointment of M/s. Bhagat & Associates as Statutory Auditors for a period of 5 years (2026-2031).
Indo Us Biotech Limited has approved the convening of its 22nd Annual General Meeting (AGM) on September 30, 2026, via video conferencing. The Board recommended the appointment of M/s. Bhagat & Associates, Chartered Accountants, as Statutory Auditors for a 5-year term from the conclusion of the 22nd AGM to the 27th AGM, subject to shareholder approval. The record cut-off date for e-voting eligibility is set for September 23, 2026, with the book closure scheduled from September 23 to September 30, 2026.
- 22nd Annual General Meeting scheduled for September 30, 2026 at 02:30 PM
- Recommendation to appoint M/s. Bhagat & Associates as Statutory Auditors for a 5-year tenure
- Remote e-voting window runs from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
- Cut-off date for voting eligibility and book closure start date set as September 23, 2026
Indo Us Biotech reported a marginal 4.3% YoY revenue growth to ₹32.09 Cr for the quarter ended June 30, 2026. However, net profit saw a sharp decline of 35.4% YoY, falling to ₹3.04 Cr from ₹4.70 Cr in the year-ago period. This margin compression was primarily driven by a 128.6% spike in finance costs and higher overall operational expenses. Consequently, the basic EPS decreased to ₹1.51 from ₹2.35 in the corresponding quarter of the previous year.
- Revenue from operations increased 4.3% YoY to ₹32.09 Cr from ₹30.77 Cr
- Net profit declined 35.4% YoY to ₹3.04 Cr from ₹4.70 Cr
- Finance costs surged 128.6% YoY to ₹60.19 lakhs from ₹26.33 lakhs
- Total expenses rose to ₹30.03 Cr compared to ₹25.95 Cr in the previous year's quarter
- Inventory changes of ₹12.16 Cr significantly impacted the quarterly cost structure
Indo Us Biotech reported a marginal 4.3% YoY increase in revenue to ₹32.09 Cr for the quarter ended June 30, 2026. However, Net Profit declined significantly by 35.3% to ₹3.04 Cr, down from ₹4.70 Cr in the same period last year. The profitability was primarily impacted by a 128% surge in finance costs and higher production expenses, leading to a drop in EPS from ₹2.35 to ₹1.51.
- Revenue from operations grew 4.3% YoY to ₹32.09 Cr from ₹30.77 Cr.
- Net Profit fell 35.3% YoY to ₹3.04 Cr compared to ₹4.70 Cr in Q1 FY26.
- Finance costs surged 128.6% to ₹0.60 Cr from ₹0.26 Cr in the year-ago quarter.
- Total expenses rose to ₹30.03 Cr from ₹25.96 Cr, outpacing revenue growth.
- Basic and Diluted EPS decreased to ₹1.51 from ₹2.35 YoY.
Indo Us Biotech Limited has announced the results of its postal ballot concluded on August 3, 2026. Shareholders approved the regularization of Mrs. Hemanshi Darsh Soni as an Independent Director for a five-year term and the appointment of M/s. Bhagat & Associates as Statutory Auditors to fill a casual vacancy. The voting saw a total turnout of 69.76%, driven primarily by 100% promoter participation, while public participation remained low at 4.64%.
- Total of 1,39,88,567 votes were polled, representing 69.76% of the total 2,00,52,000 shares
- Promoter group cast 1,36,93,643 votes, representing 100% of their holding, all in favor of the resolutions
- Mrs. Hemanshi Darsh Soni regularized as Independent Director for a 5-year term effective from April 21, 2026
- Public non-institutional participation was low, with only 2,94,924 shares (4.64% of the category) voting
- M/s. Bhagat & Associates appointed as Statutory Auditors to hold office until the next Annual General Meeting
Indo Us Biotech shareholders have approved the regularization of Mrs. Hemanshi Darsh Soni as an Independent Director and the appointment of M/s. Bhagat & Associates as Statutory Auditors. The postal ballot process, which concluded on August 3, 2026, saw a total of 1,39,88,567 votes cast out of 2,00,52,000 total shares. Both resolutions passed with near-unanimous support, including 100% of the promoter group's 1,36,93,643 shares. The voting turnout represented approximately 69.76% of the total share capital.
- Total of 1,39,88,567 votes cast out of 2,00,52,000 total shares, representing a 69.76% turnout
- 100% of promoter votes (1,36,93,643 shares) were cast in favor of both resolutions
- 4,774 shareholders were eligible to vote as of the record date of June 26, 2026
- Public non-institutional shareholders cast 2,94,924 votes, with 99.99% in favor
Indo Us Biotech Limited has submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended June 30, 2026. The company confirmed that while all 6 required events for the current quarter were captured, a technical software failure resulted in the loss of historical SDD records. Management has initiated a Root Cause Analysis (RCA) with the software vendor and implemented new backup and data verification protocols to prevent recurrence. This filing is a mandatory disclosure under SEBI (Prohibition of Insider Trading) Regulations.
- 6 events were required to be captured in the SDD during the quarter, and all 6 were successfully recorded.
- Historical SDD records became unavailable and unretrievable due to an unforeseen technical software issue.
- The company's database is designed to be non-tamperable with a record maintenance capability of 8 years.
- Corrective actions include requesting a Root Cause Analysis (RCA) from the vendor and strengthening internal monitoring controls.
Indo Us Biotech Limited has announced the resignation of its statutory auditor, M/s. Gautam N Associates, effective June 15, 2026. The outgoing auditor cited 'administrative and operational restructuring' as the reason for resignation and confirmed there are no other material concerns. The Board has appointed M/s. Bhagat & Associates as the new statutory auditor, subject to shareholder approval at the next General Meeting. This change follows the previous auditor's re-appointment for a five-year term just months earlier in October 2025.
- M/s. Gautam N Associates resigned as Statutory Auditor effective June 15, 2026
- M/s. Bhagat & Associates appointed as the new auditor by the Board on June 16, 2026
- Outgoing auditor had recently been re-appointed for a 5-year term on October 14, 2025
- Last audit report for FY26 was submitted by the outgoing auditor on May 29, 2026
- Auditor confirmed no inability to obtain audit evidence or management-imposed limitations
Indo Us Biotech Limited has announced a change in its statutory auditors, with M/s. Bhagat & Associates replacing M/s. Gautam N Associates effective June 15, 2026. The outgoing auditor resigned citing administrative and operational restructuring, explicitly stating there were no concerns or limitations in obtaining audit evidence. The new appointment was approved by the Board on June 16, 2026, and is subject to shareholder approval at the next General Meeting. This revised filing follows a query from BSE to ensure compliance with SEBI's 2019 circular on auditor resignations.
- M/s. Gautam N Associates resigned as Statutory Auditor effective 15th June 2026
- M/s. Bhagat & Associates appointed by the Board on 16th June 2026 until the next General Meeting
- Outgoing auditor confirmed 'No' concerns or inability to obtain sufficient audit evidence prior to resignation
- The previous auditor had recently been re-appointed on 14th October 2025 for a second five-year term
- Last audit report for the year ended 31st March 2026 was submitted on 29th May 2026
Indo Us Biotech Limited has updated the composition of its key board committees effective July 10, 2026. This administrative move follows the appointment of Mrs. Hemanshi Darsh Soni as an Additional Independent Director on April 21, 2026, replacing Mrs. Nehaben Patel. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees have all been reconstituted to ensure compliance with SEBI (LODR) Regulations. The board meeting was brief, lasting 30 minutes to finalize these governance updates.
- Board meeting held on July 10, 2026, concluded within 30 minutes (15:00 to 15:30).
- Mrs. Hemanshi Darsh Soni (DIN: 11659183) added to 3 major board committees.
- Audit Committee now comprises 4 members, led by Chairperson Ritaben Nileshbhai Kikani.
- Reconstitution follows the director appointment made on April 21, 2026.
- Changes are effective immediately from July 10, 2026, to meet SEBI and Companies Act requirements.
Indo Us Biotech Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar, Bigshare Services Private Limited, confirmed that no securities were received for dematerialization during the quarter from April 1, 2026, to June 30, 2026. As a result, no certificates were mutilated or cancelled, and no names were substituted in the register of members. This filing is a routine regulatory requirement for all listed entities in India.
- Quarterly compliance period ended June 30, 2026
- Zero (0) securities were received from depository participants for dematerialization
- No certificates were mutilated or cancelled during the period from March 31, 2026, to June 30, 2026
- Confirmation provided by Registrar and Share Transfer Agent, Bigshare Services Private Limited
The promoter of Indo Us Biotech Limited, Jagdishkumar Devjibhai Ajudiya, has filed a formal declaration under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The filing confirms that the promoter group holds 1,36,93,643 shares, representing a 68.29% stake in the company. Most importantly, the declaration states that no shares were encumbered or pledged, directly or indirectly, during the entire financial year. This routine disclosure provides transparency regarding the stability of the promoter's equity position.
- Promoter group held 1,36,93,643 shares as of March 31, 2026
- Total promoter stake is confirmed at 68.29% of the company
- Zero (0) shares were encumbered or pledged during the financial year 2025-26
- Promoter holding decreased slightly from 70.18% in December 2025 to 68.29% in March 2026
Indo Us Biotech has issued a postal ballot notice to shareholders for two key resolutions. The company is seeking to regularize the appointment of Mrs. Hemanshi Darsh Soni as an Independent Director for a 5-year term starting April 21, 2026. Additionally, it proposes the appointment of M/s. Bhagat & Associates as Statutory Auditors to fill a casual vacancy following the resignation of the previous auditor. The e-voting process will conclude on August 3, 2026, with results expected by August 5, 2026.
- E-voting period is scheduled from July 5, 2026, to August 3, 2026
- Cut-off date for determining shareholder voting eligibility was June 26, 2026
- Proposed Independent Director term is for 5 years effective from April 21, 2026
- New Statutory Auditor M/s. Bhagat & Associates (FRN: 101100W) to fill casual vacancy until the next AGM
Indo Us Biotech Limited is initiating a postal ballot process to regularize the appointment of Mrs. Hemanshi Darsh Soni as a Non-Executive Independent Director for a five-year term. The board has also proposed the appointment of M/s. Bhagat & Associates as Statutory Auditors for a five-year period effective from June 16, 2026. Shareholders can participate in the e-voting process from July 5, 2026, to August 3, 2026, with the final results to be declared by August 5, 2026. The cut-off date for eligibility was June 26, 2026.
- Proposed appointment of Mrs. Hemanshi Darsh Soni as Independent Director for a 5-year term starting April 21, 2026.
- Proposed appointment of M/s. Bhagat & Associates as Statutory Auditors for a 5-year term starting June 16, 2026.
- E-voting period for shareholders is scheduled for 30 days, ending on August 3, 2026.
- Cut-off date for determining shareholder eligibility was June 26, 2026.
- Scrutinizer appointed for the process is M/S Amrish Gandhi & Associates, Practicing Company Secretary.
Financial Performance
Revenue Growth by Segment
The company reported a standalone total income of INR 3,087.27 Lakhs for Q2 FY26, representing a growth of 39.14% YoY compared to INR 2,218.79 Lakhs in Q2 FY25. For the half-year ended September 30, 2025, revenue reached INR 6,164.38 Lakhs, up 31.34% from INR 4,693.36 Lakhs in H1 FY25.
Geographic Revenue Split
Not explicitly disclosed in percentage terms, but the company is headquartered in Ahmedabad, Gujarat, and is expanding its footprint through participation in the APSA Seed Congress 2025 to target global export markets.
Profitability Margins
Net Profit Margin for Q2 FY26 stood at 11.18%, a contraction from 19.65% in Q2 FY25. Net profit for Q2 FY26 was INR 345.21 Lakhs, down 20.81% YoY from INR 435.95 Lakhs, despite the revenue increase, suggesting significantly higher operational or input costs.
EBITDA Margin
Profit Before Tax (PBT) margin for Q2 FY26 was 11.53% (INR 355.89 Lakhs) compared to 20.04% (INR 444.58 Lakhs) in Q2 FY25, reflecting a decline in core operational profitability of approximately 851 basis points.
Capital Expenditure
Historical equity share capital remains stable at INR 2,005.20 Lakhs. Other equity (excluding revaluation reserves) was reported at INR 5,846.65 Lakhs as of March 31, 2025.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company maintains a paid-up equity share capital of INR 2,005.20 Lakhs with a face value of INR 10 per share.
Operational Drivers
Raw Materials
Specific raw materials include parent seeds, foundation seeds, and agricultural inputs required for hybrid seed production, which constitute the primary cost of goods sold.
Import Sources
Primary sourcing and production activities are centered in Gujarat, India, with the registered office located in Ahmedabad.
Key Suppliers
Key related party suppliers and entities include Shree Patel Beej Nigam, Indo US Agriseeds Pvt. Ltd., Patel Beej Nigam, and Agri Pari E Commerce Pvt Ltd.
Capacity Expansion
The company is a DSIR-registered research-based seed entity. While specific MT capacity is not disclosed, it is actively showcasing new high-yield hybrid and research-based varieties at international forums like the APSA Seed Congress 2025.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the decline in net profit despite a 39% revenue jump in Q2 FY26 indicates a sharp rise in procurement or production costs.
Manufacturing Efficiency
Efficiency is driven by DSIR-registered R&D activities, focusing on high-yield varieties to improve output per acre for end-users.
Logistics & Distribution
Distribution is handled through a network of vendors and partners, including Agri Pari E Commerce Pvt Ltd for digital/modern trade reach.
Strategic Growth
Expected Growth Rate
31%
Growth Strategy
Growth is targeted through participation in the APSA Seed Congress 2025 to secure global partners and expand exports. The strategy focuses on launching high-yield hybrid varieties and leveraging its DSIR-registered R&D status to gain market share in the research-based seed segment.
Products & Services
High-yield hybrid seeds, research-based crop seeds, and various agricultural seed varieties.
Brand Portfolio
Indo Us Agriseeds, Indo Us Bio-Tech.
New Products/Services
The company is introducing new high-yield hybrid and research-based varieties; participation in global congresses suggests a focus on export-oriented seed technology.
Market Expansion
Expansion into global seed markets via the APSA Seed Congress 2025 held in Mumbai to connect with international partners.
Market Share & Ranking
Positioned as a leading DSIR-registered and NSE/BSE listed seed company in India.
Strategic Alliances
Collaborations with related parties like Indo US Agriseeds Pvt. Ltd. and Shree Patel Beej Nigam for production and distribution.
External Factors
Industry Trends
The industry is shifting toward biotech-enhanced and climate-resilient seeds. INDOUS is positioning itself as a technology-driven player by focusing on high-yield hybrids and global research trends.
Competitive Landscape
Competes with both domestic seed companies and multinational biotech firms in the hybrid seed segment.
Competitive Moat
The primary moat is the DSIR-registered R&D status and proprietary seed varieties, which provide a durable advantage through intellectual property and higher crop yields for farmers.
Macro Economic Sensitivity
Highly sensitive to agricultural GDP and rural income levels, which dictate the purchasing power of the primary consumer base (farmers).
Consumer Behavior
Farmers are increasingly shifting toward branded, high-yield research seeds over traditional varieties to ensure better ROI on farming inputs.
Geopolitical Risks
Trade barriers in global seed exports could impact the expansion plans showcased at the APSA Seed Congress.
Regulatory & Governance
Industry Regulations
Subject to Seed Act regulations, DSIR certification standards, and agricultural quality norms for hybrid seed production.
Environmental Compliance
The company complies with agro-based industry standards; specific ESG costs were not disclosed.
Taxation Policy Impact
The effective tax rate for H1 FY26 was approximately 2.67% (INR 22.43 Lakhs tax on INR 837.88 Lakhs PBT).
Legal Contingencies
No significant and material orders were passed by regulators, courts, or tribunals impacting the going concern status or future operations.
Risk Analysis
Key Uncertainties
Seasonal dependency and climate risk could impact seed production and sales by 15-20% in a poor monsoon year.
Geographic Concentration Risk
High concentration in Gujarat, with the registered office and primary operations based in Ahmedabad.
Third Party Dependencies
Significant reliance on related parties like Shree Patel Beej Nigam for operational arrangements.
Technology Obsolescence Risk
Risk of proprietary seed varieties being superseded by newer biotech innovations; mitigated by continuous R&D investment.
Credit & Counterparty Risk
Receivables quality is linked to the financial health of the agricultural distribution network.
